Sugi Predict

Sugi Predict / Compounds / SCHEMBL497627

SCHEMBL497627

SCHEMBL497627

NC(Cc1c(O)[nH]c2ccccc12)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.55
▸ MAPT P10636 3/20 0.55
▸ LMNA P02545 2/20 0.55
▸ TSHR P16473 2/20 0.55
▸ BLM P54132 2/20 0.55
▸ PMP22 Q01453 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ MPO P05164 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ EGFR P00533 4/20 0.50
▸ SRC P12931 2/20 0.50
▸ SCN9A Q15858 1/20 0.50
▸ SLC7A5 Q01650 2/20 0.49
▸ ALPI P09923 1/20 0.49
▸ PKM P14618 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ XIAP P98170 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415605 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL471925 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL6295317 1.00 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
Water SCHEMBL29189815 0.98 KDM4E (0.54) KDM4EMAPTLMNATSHRBLM
Sulfurous Acid SCHEMBL28577186 0.94 MAPT (0.50) KDM4EMAPTLMNATSHRBLM
Tryptophan SCHEMBL2721525 0.89 KMT2A (0.76) KDM4EMAPTLMNATSHRBLM
SCHEMBL27795130 0.88 SLC1A1 (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL2263891 0.85 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL7694812 0.85 KDM4E (0.55) KDM4EMAPTLMNATSHRBLM
SCHEMBL7694420 0.84 KDM4E (0.54) KDM4EMAPTLMNATSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4203948-A1 COMPOSITIONS AND USES THEREOF Purposeful, Ike (GR) 2023-07-05 — — EP claimed
CN-115541767-A Method for detecting tryptophan impurity G in compound amino acid injection and application thereof 四川科伦药业股份有限公司 2022-12-30 — — CN claimed
WO-2022079304-A1 COMPOSITIONS AND USES THEREOF PURPOSEFUL IKE (GR) 2022-04-21 — — WO claimed
CN-106749497-B Chemical total synthesis of lasso polypeptide 陈铭 2020-10-30 — — CN claimed
CN-111537637-A Method for directly measuring 3 degradation products of tryptophan in compound amino acid injection 山东齐都药业有限公司 2020-08-14 — — CN claimed
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-08-06 — — US claimed
EP-3678683-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF Fog Pharmaceuticals, Inc. (US) 2020-07-15 — — EP claimed
CN-111372942-A β -catenin function modulating agents and methods thereof 弗格制药有限公司 2020-07-03 — — CN claimed
WO-2019051327-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2019-03-14 — — WO claimed
EP-3335720-A1 C-DI-GMP BINDING PEPTIDES Universität Basel (CH) 2018-06-20 — — EP claimed
WO-2004021981-A2 METHODS FOR THE PREPARATION OF β-AMINO ACIDS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2004-03-18 — — WO claimed
US-20030113882-A1 Methods for the preparation of beta-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION 2003-06-19 — — US claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
US-4283337-A Process for the purification of tryptophane and derivatives of tryptophane DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1981-08-11 — — US claimed
US-20250100967-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING Enveric Biosciences Canada Inc. (CA) 2025-03-27 — — US disclosed
CN-119564868-A Compound amino acid injection and stabilizer and preparation method thereof 远大医学营养科学(武汉)有限公司 2025-03-07 — — CN disclosed
US-12187679-B2 Hydroxylated psilocybin derivatives and methods of using Enveric Biosciences Canada Inc. (CA) 2025-01-07 — — US disclosed
WO-1995007920-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1995-03-23 — — WO disclosed
WO-1995007919-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1995-03-23 — — WO disclosed
US-4283337-A Process for the purification of tryptophane and derivatives of tryptophane DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1981-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF CTNNB1, CTNNBL1, CTNNA1 KDM4E 1902/4885MAPT 3674/4885LMNA 445/4885
US-20250100967-A1 HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING HTR1B, HTR2B, CYP8B1 KDM4E 2536/4885MAPT 2086/4885LMNA 4415/4885
US-12187679-B2 Hydroxylated psilocybin derivatives and methods of using HTR1B, HTR2B, CYP8B1 KDM4E 2536/4885MAPT 2086/4885LMNA 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.